Traws Pharma Inc (TRAW) Stock Price, Quote & News

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3680

Fax: 267 759 3681

Website: www.trawspharma.com

Address:

12 Penns Trail, Newtown, United States

DaBullhead Dec. 24 at 3:05 PM

$TRAW I really hope this stock makes you all a lot of money, but based on my ~5 years holding and averaging down, I know it’s not going to. I didn’t listen to others warning me back in the day and had to learn the hard way. This is my warning to those thinking about jumping in after reading all the bullish pump posts…look elsewhere! There are much better investments out there.

1 · Reply

Schube1255 Dec. 23 at 3:55 PM

$TRAW c'mon Traw - give us something, Happy Holiday - my xmas tree is almost ready to cut

0 · Reply

bryerchase1986 Dec. 22 at 4:54 PM

$TRAW

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 4

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 3

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 1

0 · Reply

solarpulsee Dec. 21 at 12:08 AM

$TRAW

0 · Reply

Radon222 Dec. 19 at 5:40 AM

$TRAW what happened this week with TRAW is another case study of never try to rationalize the irrational. Micro cap markets are in collusion to maximize profit by securities dealers. FINRA has to go. Simple. Eventually this shit of the rich becoming richer while those who put in the huge amount of hours to research putting their hard earned money into what says gains ahead lose will lead to a revolution. History says so.

0 · Reply

Schube1255 Dec. 19 at 3:54 AM

$TRAW Great report on biospace - Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients - BioSpace https://share.google/fUYkHzw6nLdo5UxNw

0 · Reply

Twitties00 Dec. 19 at 12:15 AM

$TRAW in studies designed to better understand its potential impact on longer-term outcomes.” 🇺🇸💎🔥

0 · Reply

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 22, 2025, 6:40 PM EDT - 2 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 14, 2025, 7:00 AM EDT - 2 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 14, 2025, 1:14 PM EDT - 4 months ago

Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 8, 2025, 7:00 AM EDT - 4 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jun 30, 2025, 6:30 AM EDT - 6 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 3, 2025, 7:00 AM EDT - 7 months ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

May 27, 2025, 8:00 AM EDT - 7 months ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 15, 2025, 7:00 AM EDT - 8 months ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Apr 1, 2025, 8:50 PM EDT - 9 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Mar 28, 2025, 4:30 PM EDT - 9 months ago

Traws Pharma Announces Management Updates

Mar 26, 2025, 7:30 AM EDT - 9 months ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 3, 2025, 7:00 AM EST - 10 months ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Feb 28, 2025, 7:00 AM EST - 10 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Aug 20, 2024, 9:02 AM EDT - 1 year ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 14, 2023, 8:18 PM EST - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 9:08 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

DaBullhead Dec. 24 at 3:05 PM

1 · Reply

Schube1255 Dec. 23 at 3:55 PM

$TRAW c'mon Traw - give us something, Happy Holiday - my xmas tree is almost ready to cut

0 · Reply

bryerchase1986 Dec. 22 at 4:54 PM

$TRAW

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 4

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 3

0 · Reply

solarpulsee Dec. 21 at 12:09 AM

$TRAW 1

0 · Reply

solarpulsee Dec. 21 at 12:08 AM

$TRAW

0 · Reply

Radon222 Dec. 19 at 5:40 AM

0 · Reply

Schube1255 Dec. 19 at 3:54 AM

0 · Reply

Twitties00 Dec. 19 at 12:15 AM

$TRAW in studies designed to better understand its potential impact on longer-term outcomes.” 🇺🇸💎🔥

0 · Reply

Dwarn2021 Dec. 18 at 10:33 PM

$TRAW wouldn’t the intellectual property alone be worth more than current market cap?

0 · Reply

Dwarn2021 Dec. 18 at 10:16 PM

$TRAW i just picked up a nice little 2,500 share order after hours.

0 · Reply

janon10 Dec. 18 at 10:08 PM

$TRAW I must say.. thank you for this gift

0 · Reply

Schube1255 Dec. 18 at 9:23 PM

$TRAW 11.19 mkt cap , almost 600mil volume ? Why is this not 10$

0 · Reply

Schube1255 Dec. 18 at 7:52 PM

$TRAW has anyone attempted to contact investor relations ...

0 · Reply

Dwarn2021 Dec. 18 at 4:22 PM

$TRAW pretty soon i will own so much no one will be able to short it. Forget about Covid and do a search for bird flu on Google and sort by date. Everything related to solutions to what is coming is going to fly.

0 · Reply

WarriorSTC Dec. 18 at 3:51 PM

$TRAW Why is the price falling despite positive news and improved strategy? Any thoughts from the 44k followers here? https://www.msn.com/en-us/money/savingandinvesting/traws-pharma-pushes-ahead-on-covid-and-flu-antivirals-as-costs-fall-and-pipeline-advances/ar-AA1QL7pn

0 · Reply

ka1954 Dec. 18 at 3:43 PM

$TRAW waited all year for all time lows? great stock

0 · Reply

WarriorSTC Dec. 18 at 3:33 PM

$TRAW will go up in coming weeks once full results are released

1 · Reply

Jbjb90 Dec. 18 at 3:20 PM

$TRAW

0 · Reply

remus630 Dec. 18 at 5:10 AM

$TRAW bought some more... thank you.. and fuck you 🖕🇬🇧 💵

0 · Reply

Oscar_66 Dec. 18 at 1:10 AM

$TRAW "Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid"... MM: "Oh NO! We must CRASH this ticker into the ground so our buddies can get onboard before $70

2 · Reply

Market Cap	9.83M
Revenue (ttm)	230,000.00
Net Income (ttm)	-166.52M
EPS (ttm)	N/A
PE Ratio	0.01
Forward PE	N/A
Profit Margin	-72,400.00%
Debt to Equity Ratio	0.00

Volume	40,700
Avg Vol	431,802
Day's Range	N/A - N/A
Shares Out	7.99M
Stochastic %K	4%
Beta	1.74
Analysts	Sell
Price Target	$8.00